Toggle Main Menu Toggle Search

ePrints

Bisphosphonate use in Duchenne Muscular Dystrophy - why, when to start and when to stop?

Lookup NU author(s): Dr Claire Wood, Professor Katherine Bushby, Professor Volker Straub, David Rawlings, Dr Anna Sarkozy, Dr Catherine Owen, Dr Timothy Cheetham

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Introduction: Long term use of glucocorticoids has dramatically improved the disease course in Duchenne Muscular Dystrophy (DMD) and patients are now frequently surviving into their thirties. However, there are significant side-effects associated with chronic glucocorticoid administration, including a reduction in bone mineral content. The resultant osteoporosis, which predisposes to fragility fractures of both long bones and vertebrae, is a major cause for concern. There is a wide variation in clinical practice regarding the use of bisphosphonates (BP) as a means of preserving skeletal integrity in this patient group.Areas covered: This review describes the rationale and evidence for use of BP in DMD, and discusses the main side-effects and limitations of their use. It will introduce the controversial concept of a bisphosphonate holiday (a break in BP therapy after a prolonged period of use) and then summarise the potential strategies for monitoring bone health when BP is stopped. It will highlight evidence from adult studies and discuss the paucity of knowledge relating to the growing skeleton.Expert Opinion: Bisphosphonates are currently the most effective therapy for steroid-induced osteoporosis in DMD but the side-effects and consequences of their long term use remain a concern. The impact of a BP holiday on the developing skeleton is unknown and further controlled studies in children are required.


Publication metadata

Author(s): Wood CL, Bettolo CM, Bushby K, Straub V, Rawlings D, Sarkozy A, Owen C, Cheetham TD

Publication type: Review

Publication status: Published

Journal: Expert Opinion on Orphan Drugs

Year: 2016

Volume: 4

Issue: 4

Pages: 407-416

Online publication date: 19/02/2016

Acceptance date: 27/01/2015

ISSN (electronic): 2167-8707

Publisher: TAYLOR & FRANCIS LTD

URL: http://dx.doi.org/10.1517/21678707.2016.1148596

DOI: 10.1517/21678707.2016.1148596


Actions

    Link to this publication


Share